News

Back

Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy

May 31st 2022

BSCB Dev

Minoryx Therapeutics, a Phase 3 stage biotech company focused on the development of treatments for orphan central nervous system (CNS) disorders, today announces it has closed a €51 million financing, including Series C equity financing and complementary bank debt. 

Read Pdf